160 participants
Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms
- Study Type:
- INTERVENTIONAL
- Last Updated:
- 2026-05-26
- Start Date:
- 2026-05-28
- Completion:
- 2030-01-01
Conditions
- Myelodysplastic Syndromes
Interventions
- DRUG
No Results Yet